This resistance to imatinib could be caused by mutations in the ABL kinase domain that reduce drug affinity or alterations in other downstream signaling pathways that increase CML cell survival5. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.